| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21044; Israel Institute for Biological Research, Ness Ziona, Israel; Centre pour le Développement des Vaccins (CVD-Mali), Bamako, Mali; National Salmonella Reference Laboratory, Centers for Disease Control and Prevention, Atlanta, GA 30333; Centro para Vacunas en Desarrollo, Hospital de Niños Roberto del Rio, Servicio de Salud Metropolitano Norte, Santiago, Chile
* To whom correspondence should be addressed. Email: mlevine{at}medicine.umaryland.edu.
| Abstract |
|---|
Polymerase chain reaction (PCR) methodology was developed to identify Salmonella enterica serovars Typhi, Paratyphi A and Paratyphi B. One multiplex PCR identifies serogroup D, A and B and Vi-positive strains; another confirms flagellar antigens "d", "a", or "b". Blinded testing of 664 Malian and Chilean Salmonella blood isolates, demonstrated 100% sensitivity and specificity.
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. |
|---|---|
| Clin. Vaccine Immunol. | ALL ASM JOURNALS |
|---|